Genentech, OSI, Roche Ltd. deal

The companies clarified their 2001 co-development and commercialization deal for Tarceva erlotinib (OSI-774) in the U.S. (see BioCentury, Jan. 16, 2001). DNA will be responsible for the marketing of T...